AbbVie and Momenta announce Humira patent licence agreement
Biotech company Momenta has obtained the rights to use AbbVie’s Humira (adalimumab) IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.
Illinois-headquartered AbbVie announced the non-exclusive global licence agreement on Tuesday, November 6.
Humira is used to treat a number of illnesses, including arthritis, Crohn’s disease, chronic psoriasis and juvenile idiopathic arthritis.
Under the terms of the deal, Massachusetts-based Momenta will pay AbbVie royalties for the use of its Humira patents. Other elements of the agreement are confidential.
The news comes shortly after AbbVie entered into a similar licensing deal with Germany-based pharmaceutical company Fresenius Kabi.
Fresenius Kabi’s US licence for the use of Humira patents will begin on September 30, 2023, and Momenta’s is due to commence on November 20, 2023.
AbbVie has also granted patent licences to Amgen (beginning January 31, 2023), Samsung Bioepis (June 30, 2023), Mylan (July 31, 2023), and Sandoz (September 30, 2023).
In the EU, Momenta can launch as soon as the European Medicines Agency (EMA) has approved M923.
Momenta said that it plans to submit a biologics licence application for M923 by the end of 2018 in the US, and a marketing authorisation (MA) application to the EMA in the first half of 2019.
Fresenius Kabi has already submitted an MA application for its adalimumab biosimilar candidate at the EMA.
Craig Wheeler, president and CEO of Momenta, said: “We are pleased to have been able to work with AbbVie on these agreements as they provide clarity as to when we will have the opportunity to expand treatment access and provide an additional high-quality option for patients who suffer from chronic inflammatory diseases.”
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk